Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Agora's intended display of IP addresses.....

< took another look at the recent 10Q and PR looking for the source of all the concerns voiced here recently.>

<In December 2009 and January 2010, we provided operational funding by loaning TPL $950,000 and $1,000,000, respectively. The $1,000,000 note which was due to be repaid by February 28, 2010 is currently in default, and we have provided a full allowance against this receivable. We do not anticipate making additional loans to TPL, and its ability to access liquidity from other sources is not certain.>

Actually, I think the underlined portion regarding TPL's ability to access liquidity is perhaps a major point of concern/wonder/guessing.

Why did PTSC feel it was necessary to include that information?

Opty

Share
New Message
Please login to post a reply